concentration 50%; HCVcc: infectious HCV particles; CC50: cytostatic concentration 50%.
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Approximately 170 million subjects are chronically infected with hepatitis C virus (HCV) worldwide. Chronic HCV infection leads to cirrhosis and hepatocellular carcinoma and causes more than 300,000 deaths per year. 1 Current treatment is based on a combination of pegylated interferon (IFN)- and ribavirin, which directly inhibits HCV replication and drives progressive infected cell clearance through intricate and only partly understood mechanisms. 2, 3 Approximately 80% of patients infected with HCV genotypes 2 or 3, but less than 50% of those infected with HCV genotypes 1 or 4, eradicate infection after pegylated IFN- and ribavirin therapy. [4] [5] [6] The need for novel, potent, well-tolerated anti-HCV therapies has stimulated the onset of a number of active drug discovery programs. 7 The most promising agents on the short-to mid-term are specific inhibitors of HCV enzyme functions.
Inhibitors of the nonstructural 3/4A (NS3/4A) serine protease of the virus are the most likely to reach the market within the next couple of years. [8] [9] [10] Nucleoside/nucleotide and non-nucleoside inhibitors of the HCV RNA-dependent RNA polymerase (RdRp) are also in development. 7 The inclusion of both IFN- and ribavirin in the treatment of chronic hepatitis C was essentially the result of empirical approaches. 11 In the search for new anti-HCV therapies, empirical approaches are still used, and several molecules are currently tested in HCV patients after having been developed for other conditions. For instance, this is the case for DEBIO-025 (Debiopharm, Lausanne, Switzerland), a cyclophilin inhibitor initially developed for the treatment of human immunodeficiency virus infection; 12, 13 nitazoxanide (Romark Laboratories, Tampa, Florida), a broad spectrum anti-parasitic agent; 14 and silibinin, the principal component of silymarin.
Silymarin is a mixture of flavonolignans extracted from the milk thistle (Silybum marianum) that has been used for many years as a "hepatoprotector" agent. The . These authors observed a significant, dosedependent reduction of HCV RNA levels upon administration, that was followed in some cases by a relapse after treatment cessation. 20 
In the present study, the principal flavonolignans contained in silymarin preparations, including silibinin A, silibinin B, their dihydrogen succinate disodium forms, isosilibinin A, isosilibinin B, silicristin, silidianin, and Legalon SIL ® were tested for their ability to directly inhibit HCV RdRp and NS3/4A protease activities in cell-free enzyme assays, while their antiviral properties were also assessed in cellular models including a subgenomic HCV genotype 1b replicon and the JFH1 infectious HCV model in Huh7 cell lines.
MATERIALS AND METHODS

Preparation of silymarin component isomers and their dihydrogen succinates
The 6 flavonolignans silibinin A, silibinin B, isosilibinin A, isosilibinin B, silicristin and silidianin; their dihydrogen disodium succinate esters; an equal mixture of silibinin A and silibinin B and of their dihydrogen succinates (the water-soluble forms used in the medical preparation); and the commercial product Legalon SIL ® (the mixture of silibinin A and B dihydrogen disodium succinates used in therapy)
were obtained from Maudaus GmbH (Cologne, Germany). They were isolated from refined and standardized milk thistle dry extract by means of organic solvents. The purity of the isolated compounds was >98% as assessed by high-performance liquid chromatography. They were then converted into their water-soluble dihydrogen disodium succinate forms. The compounds were dissolved in DMSO as a 100 mM stock and stored at -20 °C. Serial dilutions were made immediately prior to the experiments to reach a constant final DMSO concentration in all reactions of 2% in cell-free assays and JFH1 infectious model and 1% in replicon experiments.
inserm-00465965, version 1 -22 Mar 2010
Other compounds
A non-nucleoside HCV RdRp inhibitor belonging to the benzimidazole family, JT-16, 21 and an -ketoamide inhibitor of HCV NS3/4A protease, telaprevir, 22 were provided by the ViRgil-DrugPharm platform of the European Network of Excellence
ViRgil on hepatitis and influenza viruses resistance.
Expression and purification of recombinant HCV NS5BΔ21 RdRp
The HCV RdRp (non-structural 5B (NS5B) protein) from the J4 genotype 1b reference strain, 23 truncated of its 21 C-terminal amino acids to ensure solubility (NS5BΔ21) and carrying a hexahistidine tag (His-Tag) at its N-terminus, was expressed in Escherichia coli C41(DE3) and purified. Briefly, cultures were grown at 37°C for approximately 1h until the culture reached an optical density of 0.6 at 600 nm. They were then induced with 1 mM isopropyl β-D-thiogalactoside for 4h at 37°C.
Cell pellets (1 L) were resuspended in a lysis buffer containing 50 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl, 0.1% Triton X100, 0.525 mg/ml lysozyme, 0.1 U/µl desoxyribonuclease and Complete TM Protease Inhibitor Cocktail Tablets (Roche Applied Science, Mannheim, Germany; one tablet for 10 purifications). After sonication, cell lysates were clarified by centrifugation at 10,000 g for 45 min at 4°C.
Chromatography was performed on a Ni-NTA column (Qiagen, Valencia, California).
The columns were washed with a buffer containing 50 mM NaH 2 PO 4 (pH 8.0), 500 mM NaCl, and 20 mM imidazole. The bound protein was eluted in 1 mL fractions with a buffer containing 50 mM NaH 2 PO 4 (pH 8.0), 500 mM NaCl, 250 mM imidazole.
NS5BΔ21-enriched fractions were selected using a Bradford colorimetric assay, and NS5BΔ21 purity was determined by Coomassie-stained SDS-PAGE analysis.
inserm-00465965, version 1 -22 Mar 2010
Purified RdRp fractions were pooled and dialyzed against a buffer containing 5 mM Tris (pH 7.5), 0.2 M sodium acetate, 1 mM DTT, 1 mM EDTA, and 10% glycerol. As shown in Figure 2A , NS5BΔ21 purity was >98%.
In order to assess the effect of amino acid substitutions conferring resistance to other specific HCV RdRp inhibitors, site-directed mutagenesis was performed using the Quick Site-Directed Mutagenesis kit (Stratagene, La Jolla, California). The tested substitutions included S282T, M423T, N316Y, H95Q, and P495L. The constructs were verified by DNA sequencing and the corresponding proteins were purified as described above.
RdRp enzyme assay
An enzyme assay was developed to measure RdRp (NS5BΔ21) polymerase activity and its inhibition. This assay is based on measurement of the amount of compound concentrations that reduced HCV replicon RNA levels by 50%, were calculated for each compound using a four-parameter curve fitting method in the Sigma Plot 10 software.
In addition, replicon-containing Huh7 cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and treated with anti-actin and anti-NS5B monoclonal antibodies. Proteins were detected by western blot using goat anti-mouse IgG conjugated with peroxidase (Biorad). Twenty-four hours later, serial dilutions of the tested compounds were added. Cells were allowed to proliferate for 3 days at 37°C. Cell viability was then assessed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetric assay. 26 The 50% cytostatic concentration (CC50), defined as the compound concentration that inhibited proliferation of exponentially growing cells by 50%, was calculated using a four-parameter logistic equation by means of Sigma Plot 10 software. Each point is the result of three experiments performed in quadruplicate.
Assessment of antiviral activity in
RESULTS
Silymarin components directly inhibit HCV NS5B RdRp in an enzyme assay
We developed an in vitro enzyme assay based on RNA duplex formation in the presence of NS5B21. This assay was used to assess the inhibitory effect of the following silymarin components on HCV RdRp: silibinin A and B and their watersoluble dihydrogen succinate forms, isosilibinin A, isosilibinin B, silicristin, silidianin, a mixture of silibinin A plus silibinin B and a mixture of their dihydrogen succinate forms, and the Legalon SIL ® solution. The NS5BΔ21 catalytic deficient mutant (NS5BΔ21-D318A), in which the catalytic aspartate at position 318 has been replaced by an alanine, was used as negative control. Benzimidazole JT-16, a specific non-nucleoside HCV RdRp inhibitor, was used as a positive control. As shown in Table 1 , the IC50 of JT-16 was 2.0±0.9 µM in our assay. Silibinin A, silibinin
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B, the mixture of silibinin A and silibinin B and Legalon SIL ® all inhibited HCV NS5BΔ21 in a concentration-dependent manner in our assay (Table 1 and Figure 3 ).
Their IC50s were of the same order (range 74.5±5.5 to 97.2±24.1 M) and there was no difference between the natural extracts and their water-soluble dihydrogen succinate forms (Table 1) . Inulin, an excipient contained in Legalon SIL ® , had no effect on HCV RdRp (data not shown). Isosilibinin A and isosilibinin B also inhibited HCV NS5BΔ21 in a concentration-dependent manner, but they were 2-3 times less potent than silibinin A, silibinin B, the mixture of silibinin A and silibinin B or Legalon SIL ® . In contrast, neither silicristin nor silidianin exerted any inhibitory effect on HCV RdRp, up to a maximum concentration of 500 µM (Table 1) . DMSO alone at the concentrations used in the experiments had no effect on RdRp activity (data not shown).
Silymarin components inhibition of HCV RdRp is not altered by amino acid substitutions known to confer resistance to specific RdRp inhibitors
Amino acid substitutions known to confer resistance to different families of specific nucleoside and non-nucleoside inhibitors of HCV RdRp were inserted in the NS5BΔ21 sequence used in our enzyme assay by means of site-directed mutagenesis. They included S282T, M423T, N316Y, H95Q, P495L, which confer resistance to 2'-methyl nucleosides, thiophenes (thumb inhibitors), benzofurans (R200 hinge inhibitor; the wild-type variant used in our assay had an asparagine [N] at position 316), benzothiadiazines (palm inhibitors), and benzimidazoles (thumbfingertips inhibitors), respectively. As shown in Figure 4 , none of the tested substitutions had an effect on silibinin or Legalon SIL ® RdRp inhibition. In contrast, RdRp susceptibility to JT-16 was significantly reduced in the presence of P495L.
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Silymarin components have no inhibitory effect on HCV NS3/4A protease in an enzyme assay
We used an in vitro enzyme assay based on FRET to assess the inhibitory effect of the same silymarin components on NS3/4A protease. The IC50 of telaprevir, a potent, specific ketoamide inhibitor of NS3/4A protease, was 0.6±0.2 µM in this assay. In contrast, none of the tested silymarin components showed any inhibitory activity in the NS3/4A protease assay, up to a concentration of 200 µM (data not shown). DMSO at the concentrations used in the experiments had no effect on NS3/4A protease activity.
Silymarin components inhibit HCV genotype 1b replicon replication in
Huh7 cells
In order to assess the antiviral activity of silymarin components that inhibit RdRp in a replicative HCV model in cellulo, subgenomic HCV genotype 1b repliconcontaining Huh7 cells were used. 27 They were treated with increasing concentrations of silibinin A, silibinin B, the mixture of silibinin A and silibinin B, Legalon SIL ® , isosilibinin A, isosilibinin B, silidianin and silicristin. As shown in Figure 5 and Table 1 western blot analysis (data not shown). Silibinin A was slightly more potent than silibinin B, isosilibinin A and isosilibinin B in this model. Silicristin and silidianin had no antiviral effect in this model, up to a concentration of 100 M (Table 1) .
Silymarin components inhibit JFH1 replication in Huh7 cells
The antiviral activity of these silymarin components was assessed in the JFH1
infectious HCV genotype 2a system, which has been described elsewhere. 25, 28, 29 For (Table 1 ).
Silicristin and silidianin had no antiviral effect in this model, up to a concentration of 100 M (Table 1) .
Silymarin components are not cytotoxic at inhibitory concentrations
As shown in Table 2 Table 2 were obtained (data not shown).
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DISCUSSION
The current treatment of chronic hepatitis C with pegylated IFN- and ribavirin eradicates HCV genotype 1, by far the most frequent HCV genotype worldwide, in only 40%-50% of treated patients. 5, 6, 20 The failure rates are similar for HCV genotype 4, the incidence and prevalence of which is increasing in intravenous drug user populations in industrialized countries. 30, 31 The need for better HCV therapies is thus urgent. Various approaches have been undertaken, most of which target specific HCV lifecycle steps, such as polyprotein processing or replication. 7 Ferenci et al. recently reported that silibinin, the principal component of silymarin, was able to significantly reduce HCV replication in patients who previously had failed to eradicate HCV on standard combination treatment. 20 The rationale for administering silibinin to these patients was that HCV-induced oxidative stress has been suggested to contribute to fibrosis and carcinogenesis, and silibinin is a known anti-oxidative agent. Therefore, the observation of an antiviral effect of silibinin was unexpected.
Silibinin was efficient when administered intravenously, as Legalon SIL Only the intravenous form of the purified silibinin component has been shown to be effective on HCV replication, 20 and the interest for its use in HCV-infected patients must be assessed. Given the IC50s observed in the present work, it is likely that a relatively high exposure is needed to obtain a significant antiviral effect. In vivo, intravenous administration of Legalon SIL ® has been associated with maximum silibinin concentrations (C max ) of the order of 17,000 ng/mL, i.e. approximately 50 M (Madaus GmbH, data on file). These concentrations are close to the IC50s observed in this study in the enzyme assay, and above the EC50s in the replicon and JFH1 models. They suggest that direct inhibition of HCV RdRp is a mechanism by which silibinin could reduce HCV replication in infected patients. Future clinical trials will be needed to assess which patients could benefit from the administration of silibinin concomitantly to pegylated IFN- and ribavirin. Second-line treatment in difficult-totreat patients, previous non-responders to pegylated IFN- and ribavirin and/or patients with severe liver disease should be explored, given the fact that an intravenous administration is required.
In conclusion, we have shown that silibinin A and silibinin B, as well as 
